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The prion protein (PrP) seems to exert both neuroprotective
andneurotoxic activities. The toxic activities are associatedwith
the C-terminal globular parts in the absence of the flexible N
terminus, specifically the hydrophobic domain (HD) or the cen-
tral region (CR). The wild type prion protein (PrP-WT), having
an intact flexible part, exhibits neuroprotective qualities by vir-
tue of diminishingmany of the cytotoxic effects of thesemutant
prion proteins (PrPHD and PrPCR) when coexpressed. The
prion protein family member Doppel, which possesses a three-
dimensional fold similar to the C-terminal part of PrP, is also
harmful to neuronal and other cells in various models, a pheno-
type that can also be eliminated by the coexpression of PrP-WT.
In contrast, another prion protein family member, Shadoo
(Sho), a natively disordered protein possessing structural fea-
tures similar to the flexible N-terminal tail of PrP, exhibits PrP-
WT-like protective properties. Here, we report that, contrary to
expectations, Sho expression in SH-SY5Y or HEK293 cells
induces the same toxic phenotype of drug hypersensitivity as
PrPCR. This effect is exhibited in a dose-dependent manner
and is also counteracted by the coexpression of PrP-WT. The
opposing effects of Shadoo in different model systems revealed
here may be explored to help discern the relationship of the
various toxic activities of mutant PrPs with each other and
the neurotoxic effects seen in neurodegenerative diseases, such
as transmissible spongiform encephalopathy and Alzheimer
disease.
The prion protein (PrP)2 is a glycosylphosphatidylinositol
(GPI)-anchored glycoprotein ubiquitously expressed in verte-
brates, reaching its highest levels in the central nervous system
(CNS) and the heart (1, 2). It is notorious for its role in neuro-
degenerative diseases, such as transmissible spongiform
encephalopathies (TSEs) (3) and Alzheimer disease (4–6).
Numerous functions have been attributed to PrP, and its
involvement in various physiological processes has been pro-
posed (7), notably normal olfactory behavior and physiology
(8), hippocampus-dependent spatial learning (9), and periph-
eralmyelinmaintenance (10). Especially interesting are its neu-
roprotective and neurotoxic functions that might be associated
with its role in neurodegenerative diseases (11–13).
This seemingly dual role might be revealed by the expression
of PrP deletion constructs lacking most of the N-terminal
domain (“Shmerling mutants”; mPrP32–121 and mPrP32–
134) (14) or only either the hydrophobic domain (“PrPHD”;
mPrP111–134) (15) or the central region (“PrPCR”;
mPrP105–125) (16) in transgenic animal models. Expression
of these proteins in mice on a PrP null background causes var-
ious symptoms of neurodegeneration, including severe ataxia,
dramatic reduction of the granular cell layer of the cerebellum,
and vacuolization and astrogliosis in the white matter, leading
to the early death of animals in a few weeks after birth in the
case of PrPCR, which causes the most severe symptoms (7,
16). A spontaneous cytotoxic effect is also apparent in cerebel-
lar granular neuron (CGN) cultures expressing these mutant
PrPs in the absence of wild type PrP (17). The presence/coex-
pression of PrP-WT can partially or completely eliminate these
spontaneous cytotoxic phenotypes in both animal and primary
cell culture models in a dose-dependent manner (18).
The othermembers of the prion protein family, Doppel (Dpl)
and Shadoo (Sho), exert neurotoxic and neuroprotective
effects, respectively, similar to those of PrP (17, 19, 20). Doppel
and Shadoo show similarity/analogy in both structural and
functional terms to either the C-terminal structured (Doppel)
or the N-terminal unstructured, flexible domain (Sho) of PrP.
All threemembers of the prion protein family localize predom-
inantly to the cell surface, being attached to the outer leaflet of
the plasma membrane via a GPI anchor (21, 22).
The ectopic expression of Doppel in the CNS causes severe
neurodegeneration, ataxia, and the loss of Purkinje cells (23–
25). Its expression in CGN culture likewise triggers increased
cell death (17, 26), akin to mutant PrPs. Interestingly, these
neurotoxic effects are also counteracted by the coexpression of
PrP-WT.
Shadoo is the most recently discovered mammalian PrP
paralog (27). Just like PrP, Shadoo appears, among other tissues,
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in the central nervous system (17). There is no extended
sequence similarity between Sho and PrP, except in their
hydrophobic domains (aa 62–77 in mouse Sho and aa 113–133
in mouse PrP). Nevertheless, both PrP flexible N-terminal part
and Sho that are natively unstructured contain repeat regions
with periodically reoccurring positively charged amino acids:
histidines in the octarepeat region of PrP and arginines in the
(RXXX)n motif of Sho (28). This structural similarity parallels
functional analogy; coexpression of Shadoo counteracts the
neurotoxic effects of Doppel and of PrP32–121 in CGN cul-
ture, and of PrPHD in human neuroblastoma SH-SY5Y cells
in a manner similar to that of PrP-WT (17, 20). Interestingly,
the latter group also reported that PrP-WT and Sho, unlike
their HD-deleted mutant variants, decrease the excitotoxic
effect of glutamate in SH-SY5Y cells, emphasizing the neuro-
protective feature of Sho that is also characteristic of PrP bear-
ing an intact N-terminal part (20). Furthermore, it was found
that both Doppel and PrPCR cause increased sensitivity to
certain drugs (hygromycin, G418, and Zeocin) in several types
of immortalized cell lines, a phenotype that was also eliminated
by PrP coexpression (29).
In addition, the same mutant PrPs in various cells with dis-
tinct origins are reported to induce inward cationic currents
detected in whole cell patch clamp experiments (30). This
interesting phenotype was also diminished by the coexpression
of PrP-WT.
Apparently, several neurotoxic and neuroprotective activi-
ties are associated with PrP and itsmutant forms. However, it is
not clear whether the manifestation of these various pheno-
types associated with PrP-WT and mutant PrPs with N-termi-
nal deletion in different model systems involve identical or dif-
ferent pathways.
In one approach, Harris and colleagues (30, 31) examined
several PrP variants bearing familial TSE-associated point
mutations in or next to the central region for a correlation
between the appearance of spontaneous inward currents and
drug hypersensitivity. Their results seem to support the exist-
ence of overlapping pathways 1) for the pathomechanisms of
some forms of familial TSE and 2) for drug hypersensitivity and
for the emergence of spontaneous inward currents.
As a different approach, the interference of Sho expression
with various toxic phenotypes related to PrP may also help
to distinguish activities that involve different pathways. To
explore this approach, we set out to learn whether the neuro-
protective potential of Sho, seen both in CGN culture and
SH-SY5Y cells expressing N-terminal deletion mutant PrPs or
Doppel and in SH-SY5Y cells by decreasing the toxic effect of
glutamate, is also manifested in reverting the drug hypersensi-
tivity phenotype caused by a deletion mutant PrP.
Experimental Procedures
Chemicals, Reagents, Antibodies
Restriction endonucleases, T4 DNA ligase, Pfu DNA poly-
merase, isopropyl -D-thiogalactopyranoside, and TurboFect
transfection reagent were purchased from Thermo Scientific.
DNA oligonucleotides were from Microsynth AG. High-glu-
cose Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were obtained from Life Technologies/
Gibco, and penicillin/streptomycin was from Lonza. 4,6-Di-
amidino-2-phenylindole (DAPI), proteinase inhibitor mixture,
calpain inhibitor I, G418, puromycin, etoposide, and 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
were obtained from Sigma-Aldrich. Bradford reagent was from
Bio-Rad. Polyvinylidene difluoride (PVDF) transfer membrane
and chemiluminescent substrate (Immobilon ECL substrate)
were fromMillipore. PNGase F was purchased from New Eng-
land Biolabs. PI-PLC, Zeocin, and PrestoBlue reagent were
obtained from Life Technologies. The following primary anti-
bodies were used: SAF32 anti-PrP mouse IgG (Cayman Chem-
ical, 189720), purified anti-H2AX.phospho antibody (Bioleg-
end, 613402), anti-Shadoo rabbit polyclonal antibody (Abgent,
AP4754b), and anti--actin chicken IgG (Sigma, GW23014).
Secondary antibodies used were goat anti-mouse IgG (HL),
Alexa Fluor 594- or Alexa Fluor 647-conjugated (Life Technol-
ogies, Inc., A11005 and A21235). Horseradish peroxidase
(HRP)-conjugated anti-mouse, anti-rabbit, and anti-chicken
IgGwere from Jackson ImmunoResearch (catalog no. 715-035-
151), Pierce (catalog no. 31460), and Sigma-Aldrich (catalog no.
A9046), respectively. All other reagents and chemicals were
purchased from Sigma-Aldrich.
Plasmid Constructs and DNA Cloning
The cDNA of mouse Shadoo protein (mSho) (Uniprot entry
Q8BWU1) in a pSPORT1 plasmid was obtained from MRC
Geneservice, and the cDNA of mouse PrP (mPrP) (Uniprot
entry P04925) was from the Caughey laboratory (32). Plasmid
vectors of the Sleeping Beauty transposon-based gene delivery
system (SB CAGx100 (33) and pSB-CAG-Puro (34)) and the
pRRL lentiviral vectors (pRRL-EF1-mCherry and pRRL-EF1-
EGFP (35)) were kind gifts of Dr. Z. Izsvák and Dr. Z. Ivics and
of Dr. K. Német, respectively. All plasmids were constructed
with standard molecular biology techniques, briefly as follows.
The deletion of the central region (aa 105–125) of mPrP in
the pcDNA3 vector and the introduction of a silent mutation
for removing the XhoI restriction site of the mSho CDS in the
pSPORT1 vector were carried out using the QuikChange site-
directed mutagenesis protocol (Stratagene) with the following
oligonucleotides: Delta105–125for and Delta105–125rev,
XhoImutator5 and XhoImutator3, respectively. Subsequently,
XhoI-mutated Shadoo was PCR-amplified, using mSho-
BamHI5 and XhoISho3 primers, and cloned to the pcDNA3
vector between the BamHI and XhoI restriction sites.
Sleeping Beauty Constructs (Fig. 1A)—The cDNA of the
enhanced green fluorescent protein (EGFP) with a Kozak
sequence was cloned into the polycloning site of the pcDNA3
eukaryotic expression vector, between the BamHI and NotI re-
striction sites. The whole expression cassette containing the
CMV-IE promoter and EGFP followed by a BGHPoly(A) signal
was amplified from the vector by PCR with the following prim-
ers: ApoICMV5 and ApoIBGH3. PCR fragments were purified
and digested by ApoI enzyme and were cloned into the EcoRI
site of a Sleeping Beauty plasmid containing a puromycin resis-
tance gene driven by a CAG promoter (pSB-CAG-Puro). The
resultant plasmid is named pSB/GFP.
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The cDNAs of wild type mPrP and mPrPCR were PCR-
amplified with the primers PrPNheI5 and PrPBamHI3 from the
pcDNA3 vectors encoding the respective constructs. Subse-
quently, after being digested with NheI and BamHI enzymes,
they were inserted downstream of the CAG promoter into the
pSB/GFP vectors, between the restriction sites of NheI and
BglII, which also removed the cDNA of the puromycin resis-
tance gene. The resulted plasmids were named pSB/PrP and
pSB/CR.
Lentiviral Constructs (Fig. 1B)—A linker (linker2-3048) con-
taining the unique sites of the AscI and BsiWI restriction endo-
nucleases was cloned into the pRRL-EF1-mCherry or pRRL-
EF1-EGFP lentiviral vector between the BsrGI and SalI sites.
The modified pRRL vectors are called LV/mCh and LV/GFP.
Expression cassettes containing the PrP or Sho coding
sequences driven byCMV-IEpromoterswere amplified byPCR
from the pcDNA3 vectors encoding the respective constructs
with the following PCR primers: V-CMV-PrP fw and V-CMV-
PrP rev (for PrP) and V-CMV-PrP fw and V-CMV-PA rev (for
Sho). The PCR products were digested and inserted between
theAscI andBsiWI sites of themodified pRRL-EF1-mCherry or
pRRL-EF1-EGFP vectors. The vectors containing PrP or Sha-
doo expression cassettes are called LV/PrP(R), LV/Sho(R), and
LV/PrP(G).
Recombinant Sho-PrP Fusion Polypeptide—The fusion poly-
peptide rSho-PrP was made by cloning a fragment that codes
for the peptide from amino acids 81–116 of Sho (TGS-
GWRRTSG PGELGLEDDE NGAMGGNGTD RGVYSYS),
corresponding to the Sho antibody epitope, into a fragment
coding for PrP(23–230) in a pET41 expression vector, between
positions corresponding to the 93rd and 94th amino acids of
PrP using three DNA linkers with overlapping overhangs (Sho-
epi1, -2, and -3) ligated into the unique Acc65 restriction
enzyme site. For the sequences of the oligonucleotides used for
PCR and linker ligation, see Table 1. The correct sequences for
the expression cassettes in all plasmids generated in this study
were confirmed by Sanger sequencing (Microsynth AG).
Expression, Purification, and Refolding of the Recombinant
Sho-PrP Fusion Protein
Plasmid pET41a encoding the rSho-PrP fusion polypeptide
encompassing both PrP and Sho epitopes was transformed
into competent Escherichia coli BL21 (DE3) pLysS, and after
induction by isopropyl--D-1-thiogalactopyranoside, it was
expressed at 37 °C in inclusion bodies. Cells were harvested 8 h
after induction. Proteins were purified as follows. Inclusion
bodies were dissolved in buffer A (6 M guanidinium chloride
(GdmCl), 100 mM Na2HPO4, 400 mM NaCl, 5 mM imidazole,
and 5 mM -mercaptoethanol, pH 8.0) and stirred overnight at
4 °C. After centrifugation, the soluble protein fraction was
transferred to a nickel-nitrilotriacetic acid-agarose column.
Before the oxidative refolding step, the column was washed
with buffer B (10 mM Tris-HCl, 100 mM Na2HPO4, pH 8.0)
containing at first 6 M GdmCl and then 1 M GdmCl. Oxidative
refolding was performed in buffer B containing 1 M GdmCl, 10
mM glutathione (reduced), 5 mM glutathione (oxidized). To
remove the nonspecifically bound protein impurities, the col-
umn was washed with buffer B containing 50 mM imidazole.
Elution was carried out with 50 mM sodium acetate, pH 4.1.
Proteins obtained were stored at80 °C until use.
Cell Lines, Culturing, Transfection, and Transduction
SH-SY5Y human neuroblastoma andHEK293 cell lines were
from ATCC (CRL-2266TM) and Gibco (11631-017), respec-
tively. Each type of cell was cultured in high glucose DMEM
complemented with 10% heat-inactivated fetal bovine serum,
100 units/ml penicillin, and 100g/ml streptomycin at 37 °C in
a humidified atmosphere with 5% CO2. Cells were passed at
90–95% confluence at 1:10 splitting ratios for each type of cells.
For transfection purposes, 1  105 SH-SY5Y cells were
seeded on multiple wells of 6-well plates. The transfection was
carried out at 50–70% confluence, using 1–4 g of circular
plasmid DNA with TurboFect transfection reagent, in accord-
ance with the manufacturer’s manual.
In the case of lentiviral transductions, the lentiviruses were
generated in the Hungarian National Blood Transfusion Ser-
vice’s lentiviral facility. The transductions of SH-SY5Y and
HEK293 cells were carried out on 24-well plates. 3  104 cells
were seeded, and the transductions were carried out for 24 h at
various multiplicities of infection from 1 to 5.
Fluorescence-activated cell sorting was used to separate cells
with stable transgene expression in the transfected or trans-
duced cell populations based on the expression of the fluores-
cent marker. In case of transfection with the Sleeping Beauty
constructs, the EGFP-positive cells were sorted at 3 and 14 days
post-transfection. In the case of transduced cells, mCherry-
positive or mCherry and EGFP double-positive cells were
sorted 7–10 days post-transduction.
All types of cells were regularly tested for mycoplasma con-
tamination. EGFP and mCherry positivity were examined at
every passage, and experiments were carried out on cultures in
which at least 90% of the cells expressed the required fluores-
centmarkers. In parallel with the execution of the experiments,
the expression levels of the transgenes were determined by an
immunoblotting technique.
TABLE 1
The DNA oligonucleotides used in the cloning processes
Oligonucleotide
name DNA sequence
Delta105–125for AACAAGCCCAGCAAACCAGGCTACATGCTGGGGAG
Delta105–125rev CTCCCCAGCATGTAGCCTGGTTTGCTGGGCTTGTT
XhoImutator5 CGGCCGCGGAGGCGCACGAGGCAGTGCCCGG
XhoImutator3 CCGGGCACTGCCTCGTGCGCCTCCGCGGCCG
ApoICMV5 CGCGCGAAATTTCTGCTTCGCGATGTACGGG
ApoIBGH3 GGCCCGAAATTTCCACCGCATCCCCAGCATG
PrPNheI5 GCCGGGCTAGCCACCATGGCGAACCTTGGCTACTG
PrPBamHI3 TACCACGGATCCTCATCCCACGATCAGGAAGATG
mShoBamHI5 CCCGAAGGATCCGCCACCATGAACTGGACTGCTGCCACG
XhoISho3 GGCGCGCTCGAGCTAAGGCCGAAGCAGTTCTAG
Linker2-3048-fwd GTACAAGTGAGGGCGCGCCAAACATATGAAACGTACGAA
Linker2-3048-rev TCGATTCGTACGTTTCATATGTTTGGCGCGCCCTCACTT
V-CMV-PrP fw TTTGCAGGCGCGCCCGATGTACGGGCCAGATATACG
V-CMV-PrP rev CACTATTGTACAGGGCCCTCTAGATGCATGCTCGAGC
V-CMV-PA rev ATAGAGTGTACAACATCCCCAGCATGCCTGC
Sho-epi1-fwd GTACAGGCTCTGGCTGGAGGAGGACCTCAGGGCCTGGAGAGCTA
Sho-epi1-reva AGGCCCTGAGGTCCTCCTCCAGCCAGAGCCT
Sho-epi2-fwda GGCCTGGAGGACGATGAGAATGGGGCAATGGGAGGC
Sho-epi2-reva TGCCCCATTCTCATCGTCCTCCAGGCCTAGCTCTCC
Sho-epi3-fwda AACGGAACCGACCGAGGAGTCTACAGCTACA
Sho-epi3-rev GTACTGTAGCTGTAGACTCCTCGGTCGGTTCCGTTGCCTCCCAT
a These oligonucleotides are 5-phosphorylated.
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Immunocytochemistry
Cells were seeded onLabtek-II 8-well slides (5 104 cell/well
density) or on 96-well plates at 1.5  104 cells/well density for
phosphorylated histone 2AX (-H2AX) detection. 24 h after
seeding, cells were fixed with 4% paraformaldehyde in PBS for
10 min at room temperature and washed three times in immu-
nofluorescence washing (IF) solution (0.2% bovine serum albu-
min, 0.1% Triton X-100 in PBS) followed by blocking and per-
meabilization using 5% bovine serum albumin, 0.5% Triton
X-100 in IF solution for 10min at room temperature. Cells were
washed again three times in IF solution before applying the
primary antibody (SAF32 anti-PrP mouse IgG for PrP staining
and purified anti-H2AX.phospho antibody for -H2AX stain-
ing) for 1 h at room temperature. The dilutions for the primary
antibodies were as follows: 1:200 SAF32 and 1:250 anti--
H2AX in IF solution. The cells were then washed once by IF
solution, and the secondary antibody (goat anti-mouse IgG
(HL) or Alexa Fluor 594 or 647) was applied for 30 min at
room temperature. All secondary antibodies were used at 1:250
dilutions in IF solution. Cells were washed threemore times for
10 min and once overnight, and then nuclei were stained with
DAPI for 10 min at room temperature (1 M DAPI in PBS).
The cells were observed using an Olympus FV500-IX confo-
cal laser scanning microscope, with a PLAPO60 (1.4 numer-
ical aperture) oil immersion objective (Olympus). DAPI, EGFP,
mCherry, and Alexa Fluor 647 fluorophores were excited at
405, 488, 543, and 633 nm, respectively. Emission detection
ranges were 430–460 nm (DAPI), 505–525 nm (EGFP), 560
nm (mCherry), and 660 nm (Alexa Fluor 647), respectively.
Confocal images were recorded with Olympus Fluoview ver-
sion 5.0 software. Image acquisition settings (laser intensity,
photomultiplier settings, and confocal aperture size for each
channel)were kept unchanged during confocalmicroscopy ses-
sions. Images were captured in sequential scanning mode and
using 1024 1024-pixel resolution.
Immunoblotting
Cells seeded on 100-mmcell culture dishes were harvested at
70–90% confluence after beingwashed oncewith PBS by scrap-
ing in 1 ml of PBS. Cells were pelleted by centrifugation (3 min,
200  g) and resuspended in ice-cold lysis buffer (50 mM
HEPES, pH 7.5, 0.2 mM EDTA, 10mMNaF, 250mMNaCl, 0.5%
Nonidet P-40, with 1% proteinase inhibitormixture, 1% calpain
inhibitor, 1mMDTT).The totalproteinconcentrationwasmea-
sured by using a Bradford protein assay. Where needed,
PNGase F treatment was carried out on samples of 50–100 g
of total protein, according to themanufacturer’s protocol. Sam-
ples of 1–50g of total protein, depending on the necessities of
the experiment, were run on 15% denaturing polyacrylamide
gels and were blotted onto activated PVDF membrane, using a
wet blotting system from Bio-Rad. Themembrane was blocked
for at least 1 h in Tris-buffered saline with Tween 20 (TBST),
containing 5% nonfat milk powder, and primary antibodies
were applied overnight at 4 °C at the following dilutions: SAF32,
1:5000; anti-Shadoo rabbit polyclonal antibody, 1:200; anti--
actin chicken IgG, 1:1000. The next day, after several washing
steps in TBST, HRP-conjugated secondary antibodies were
applied to the membrane for 60 min in the following dilutions:
anti-mouse (1:20,000) and anti-rabbit and anti-chicken anti-
bodies (1:200,000) in blocking buffer. The proteins were visual-
ized by adding chemiluminescent substrate (Millipore Immo-
bilon ECL substrate).
Phosphatidylinositol-dependent Phospholipase C (PI-PLC)
Treatment
Cells were seeded on 24-well plates. After reaching conflu-
ence, the PI-PLC treatment was carried out according to the
manufacturer’s protocol. Briefly, cells were washed twice in
PBS, and the plate with cells having only PBS or PBS with PI-
PLC (1 unit/ml PI-PLC) was rocked gently for 30 min at 4 °C.
The supernatants were removed from the cells, centrifuged (5
min, 20,000 g) to remove cells and debris, and processed for
SDS-PAGE (noted as medium (M) samples in Fig. 4). The PI-
PLC-treated and untreated cells were harvested from the plates
by scraping and were processed for SDS-PAGE (noted as cell
lysate (Cl) samples in Fig. 4).
Cell Viability Assays
Cells stably transfected or transduced were seeded onto
96-well plates at 3  104 cells/well density (SH-SY5Y cells) or
1 104 cells/well density (HEK293 cells). After the attachment
of the cells, themediumwas changed to freshmedium contain-
ing serial dilutions of various drugs; Zeocin and G418 treat-
ments were administered for 48 h, and puromycin treatment
was administered for 24 h. The measurement of PrPCR-in-
duced Zeocin hypersensitivity (Fig. 3, A and B) was carried out
usingMTT; all other cell viability assays were carried out using
PrestoBlue reagent according to the manufacturer’s protocol,
briefly as follows.
MTTAssay—After drug treatment, themediumwas changed
to PBS containing 0.5g/mlMTT, and plates were placed back
into the cell culture incubator. After 4 h of incubation, MTT
solution was carefully removed, and the converted dye was sol-
ubilized in acidic isopropyl alcohol (isopropyl alcohol plus 1 N
HCl, 9:1), and the absorbance of the solution was measured at
560 nm.
PrestoBlue Assay—After the drug treatment, the medium
was changed to PBS containing 5% PrestoBlue, and cells were
placed back for 60 min into the CO2 incubator before measur-
ing fluorescence with a PerkinElmer Enspire multimode plate
reader (excitation, 555 nm; emission, 585 nm).
Analysis of cell proliferation was carried out using 96-well
plates and the PrestoBlue assay. About 4 h after seeding, when
cell attachmentwas confirmedbymicroscopy analysis, the fluo-
rescence in 4 wells of each cell type wasmeasured in order to be
used as initial values. After every 24 h for 8 days, 4 wells of each
cell weremeasured, and themeasured fluorescence values were
normalized to the initial values to estimate the change in the
number of cells.
Detection of Histone 2AX Phosphorylation—SH-SY5Y cells
expressing either Sho, PrPCR, or their respective controls,
mCherry or EGFP, were seeded on 96-well plates at 1.5  104
cells/well density. 24 h after seeding, the cells were subjected to
0, 20, or 100g/mlZeocin or 50Metoposide in normal culture
Drug Hypersensitivity Caused by the Shadoo Protein
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medium for 60min at 37 °C and thenwashed oncewith PBS and
immunostained as described above.
Image acquisition was performed with an ImageXpress
MicroXLS high content screening system (Molecular Devices),
using a Nikon10 plan fluor objective (numerical aperture
0.3). Blue and far-red fluorescence signals ofDAPI and-H2AX
for nuclei were detected using emission filters of 447/60 nmand
692/40 nm, respectively, with 377/50- and 635/18-nm excita-
tion filters, and 4–6 fields of view were imaged per well. For
analysis, the cells were segmented on the basis ofDAPI staining,
and the percentage of -H2AX-positive nuclei was determined
using the MetaXpress software. At least 4000 cells were ana-
lyzed per condition.
Image Analysis—Microscopy images were analyzed using the
ImageJ version 1.48 software with Bio-Formats plugin. During
image processing, the lookup tables were always linear and cov-
ered the full range of the data.
Statistics
Cell viability assays were done with five parallel samples for
every condition. The number of surviving cells in the case of
each drug concentration was normalized to the number of cells
receiving no drug treatments. For statistical analysis, one con-
centration was chosen from each drug treatment: 6.25 g/ml
forZeocin, 250g/ml forG418, and 1.6g/ml for puromycin in
the case of SH-SY5Y cells and 50 g/ml for Zeocin and 250
g/ml for G418 in the case of HEK293 cells.
Statistical analysis (normality tests, Student’s t tests, and one-
way analyses of variance with two-tailed Dunnett’s or Tukey’s
HSD post hoc tests) was carried out on data from at least three
independent experiments with SPSS Statistics version 20 soft-
ware. On plots, mean  S.D. values are shown. p values are as
follows: *, 0.01	 p	 0.05; **, 0.001	 p	 0.01; ***, p	 0.001.
Results
Establishment of the Cell CultureModel Systems—In order to
examine the effect of Shadoo expression on the toxic effect of
PrPCR, we established a vector system that allows the effec-
tive use of both transient and stable expressions in cell cultures.
Because of the lack of an appropriate anti-Sho antibody for
immunocytochemistry and to avoid the adverse effects of tag-
ging Shadoo (i.e. loss of Shadoo function), we used individual
fluorescent proteins (EGFP ormCherry) whose expressions are
tightly coupled to the expression of the target proteins. Thus,
the successfully transfected cells transiently expressing the tar-
get protein could be identified and examined separately from
the untransfected cell population by fluorescence microscopy.
Alternatively, the cells with stable transgene integration could
be selected by using fluorescence-activated cell sorting (FACS).
In order to average out the potential positional effects of indi-
vidual integrations on the outcome of the experiments, the sta-
bly transfected cell population was used without establishing
individual clones. The tight coupling between the expression
of the target and marker protein is achieved through two
approaches: the use of either 1) the Sleeping Beauty trans-
poson-based gene delivery system (SB) (36) or 2) a lentiviral
approach (37).
SB ensures the collective insertion of the two expression cas-
settes between the transposon arms, resulting in over 95% cou-
pling (data not shown). When a second transgene expression
was required, we used lentivirus for the collective integration of
the second transgene with the second fluorescent marker. In
order to find sufficiently high Shadoo expression, two virus vec-
tors containing expression cassettes in different orientations in
respect to each other were tested. Viruses with a “tandem” ori-
entation were chosen, because this resulted in a higher mSho
expression (data not shown). The cells generated are listed in
Table 2, and the topologies of the plasmid constructs are shown
in Fig. 1.
First, using SB, we established stable expressions of PrPCR,
PrP-WT, and EGFP in Zpl2-1 immortalized hippocampal
Prnp-knock-out cells (38) and in SH-SY5Y human neuroblas-
toma cells that usually exhibit no detectable endogenous PrP
expression (20, 39).
Their expression is corroborated by immunocytochemistry
and immunoblotting (Fig. 2, A and B). PNGase F (Fig. 2B) and
PI-PLC treatments (Fig. 2C) confirmed that both wild type and
mutant PrPs are properly processed,N-glycosylated, acquired a
GPI anchor, and are localized on the cell surface.
Cell Protective and Toxic Effects of the PrP Constructs—We
were not able to detect any significant spontaneous toxicity
associatedwith the expression of PrPCR inZpl2-1 as tested by
annexin staining using FACS.3 Several reports suggested that
PrPC exerts a cytoprotective activity that prevents the death of
neurons and other cells caused by toxic stimulus (39–44).
However, we were unable to detect a significant anti-apoptotic
effect of PrP-WTexpression under the condition of serumdep-
rivation in Zpl2-1 cells.3 These results are in line with a former
report where no robust cytoprotective effect of PrP was found
in the various models tested (45). Because Zpl2-1 cells repeat-
edly lost the expression of the transgenes during our work,
thwarting progress, we used the SH-SY5Y cells for further
studies.
PrPCR is reported to cause hypersensitivity to Zeocin- and
G418-related antibiotics, which is eliminated by PrP-WT coex-
pression (29). The expression of PrPCR caused Zeocin hyper-
sensitivity in SH-SY5Y cells (Fig. 3, A and B) that was dimin-
3 A. Nyeste and E. Welker, unpublished data.
TABLE 2
Cells with stable transgene expression used in these studies
The given abbreviated names and the specifics for each type of transformant cell are
listed.
Cell culture
name Introduced transgenes Parental cell name
Vector
used
SH/GFP EGFP SH-SY5Y pSB/GFP
SH/PrP mPrP and EGFP SH-SY5Y pSB/PrP
SH/CR mPrPCR and EGFP SH-SY5Y pSB/CR
SH/mCh mCherry SH-SY5Y LV/mCh
SH/Sho mSho and mCherry SH-SY5Y LV/Sho(R)
SH/CRmCh mCherry SH/CR LV/mCh
SH/CRPrP mPrP and mCherry SH/CR LV/PrP(R)
SH/CRSho mSho and mCherry SH/CR LV/Sho(R)
SH/ShoGFP EGFP SH/Sho LV/GFP
SH/ShoPrP mPrP and EGFP SH/Sho LV/PrP(G)
HEK/mCh mCherry HEK293 LV/mCh
HEK/Sho mSho and mCherry HEK293 LV/Sho(R)
HEK/ShoGFP EGFP HEK/Sho LV/GFP
HEK/ShoPrP mPrP and GFP HEK/Sho LV/PrP(G)
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ished by the coexpression of PrP-WT (Fig. 3, C and D). These
data are in agreement with those obtained using different cells,
such as HEK, CHO, and mouse neural stem cells (29, 46–48).
Shadoo Expression Causes Drug Hypersensitivity—To assess
whether Sho expression exerts a PrP-WT-like effect on these
phenotypes, we introduced Sho into SH/CR cells by lentivirus.
The transduction itself did not have an adverse effect on the
proliferation of the resulting SH/CRSho cells (Fig. 4A). The
plasma membrane localization is a prerequisite for PrPCR
neurotoxicity and probably for the neuroprotective activities of
PrP-WT (46, 47). PNGase F and PI-PLC treatment indicated
that Sho expressed here, like PrP, is both complex-glycosylated
(Fig. 4,B andC) and attached to the cell surface via aGPI anchor
(Fig. 4,D andE). An expression level of PrP-WT that is identical
to that of PrPCR (Fig. 4F) is sufficiently high in SH/CRPrP
cells to effectively eliminate the drug hypersensitivity pheno-
type of PrPCR (Fig. 3,C andD). The expression level of Sho, as
determined byWestern blotting using an rPrP-Sho fusion poly-
peptide (Fig. 4G), is comparable with that of PrPCR in
SH/CRSho cells (Fig. 4H). However, contrary to expecta-
tions, Sho expression does not diminish PrPCR-induced Zeo-
cin hypersensitivity when expressed in SH/CR cells (Fig. 3, C
and D).
More surprisingly, the Sho-expressing control SH-SY5Y cells
(SH/Sho; Table 2), like SH/CR, showed hypersensitivity to
Zeocin and G418 but not to puromycin (Fig. 5, A–F) in a dose-
dependent manner (Fig. 5, G–I). These hypersensitivities are
also eliminated by the coexpression of PrP-WT with Sho (Fig.
6), as has been demonstrated for PrPCR (Fig. 3, C and D).
These phenomena were also observed in HEK293 cells (see
Table 2 for cell lines).HEK/Sho cells, which overexpress Shadoo
protein (Fig. 7, A and B), are more sensitive to Zeocin (Fig. 7, C
and D) or G418 (Fig. 7, E and F) than HEK/mCh cells, and the
hypersensitivity to both drugs is eliminated by the co-expres-
sion of wild type PrP (Fig. 7, C–E).
Zeocin causes double strand breaks to DNA, triggering the
recruitment and phosphorylation of histone 2AX at the break
points (49). It has been shown that PrPCR causes an increased
initial uptake of Zeocin, as assessed by histone 2AX immuno-
cytochemistry (29, 49).
We observed an increased number of -H2AX-positive
nuclei in SH/PrPCR cells comparedwith that seen in SH/mCh
cells (Fig. 8, A and B), consistent with earlier reports (29). Sim-
ilarly, a substantial increase was seen in the number of
-H2AX-positive nuclei in Sho-expressing cells (Fig. 8, A and
C); however, this effect was less pronounced despite the higher
expression of Shadoo in SH/Sho cells as compared with that of
PrPCR in SH/CR cells (Fig. 8D). These results suggest that
both Shadoo and PrPCR augment cellular uptake of Zeocin,
although Shadoo might be less effective.
Discussion
One of the most challenging questions in prion biology is
how the various forms of PrPs cause/contribute to the neuro-
degeneration seen in diseases such as Alzheimer disease and
prion diseases in humans (familial, infectious, and sporadic
forms), in ruminant, or even in model transgenic animals (7).
Some transgenic mice expressing N-terminal deletion mutant
forms of PrP on a PrP/ background exhibit a lethal neurode-
generative phenotype that is dose-dependently suppressed by
the coexpression of PrP-WT (14–16). This latter finding sug-
gests that these deletion mutant PrPs subvert a normal func-
tional activity of the prion protein and have long been studied
with the expectations that these mechanisms might be the
underlying cause of the neuronal loss apparent in some neuro-
degenerative disorders (11). Although these N-terminal dele-
tion mutant PrPs do not cause any apparent toxic phenotype
when expressed in immortalized cells, they cause hypersensi-
tivity to a few cationic members of two classes of antibiotics,
glycopeptides (Zeocin and bleomycinD1) and aminoglycosides
(G418 and hygromycin) (29). Here, we found that the expres-
sion of Sho, like that of mutant PrPs, also makes SH-SY5Y and
HEK293 cells hypersensitive to these two types of antibiotics
and that the Sho-induced hypersensitivities are also diminished
by the coexpression of PrP-WT.
These findings are surprising, because Sho is generally
regarded as an analogue of PrP-WT, specifically an analogue of
the N-terminal half of PrP, in paradigms where PrP exhibits a
neuroprotective, cytoprotective activity (17, 20, 21). Here, not
only does Sho not exhibit PrP-like cell protective activity; it
actually mediates a toxic effect. This might reflect a role for the
disordered N-terminal part of PrP in toxic phenotypes too (46,
48). Indeed, neurotoxic signals triggered by an interaction of
PrP with certain anti-prion monoclonal antibodies were
FIGURE 1. Topologies of the plasmid constructs used in these studies. A,
Sleeping Beauty plasmids used for integration of the expression cassettes. B,
pRRL plasmids used for lentivirus generation. IR-L and IR-R, left and right
inverse repeats of SB. LTR-5 and LTR-3, 5 and 3 long terminal repeats. CMV,
CMV intermediate early promoter. CAG, CMV early enhancer/chicken -actin
promoter. EF1, elongation factor-1 promoter. PuroR, puromycin resistance
gene. PrP-wt, wild type mouse prion protein. PrPCR, mouse prion protein
missing the central region (aa 105–125). Sho, mouse Shadoo protein.
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reported to critically depend on the flexible N-terminal part of
PrP (50).
PrPCR and Sho Explore Identical Cellular Pathways to
Induce Zeocin/Drug Hypersensitivity—Zeocin and G418 are
unrelated in their chemical structure, cellular target, andmech-
anism of action. The specificity of how Sho renders cells hyper-
sensitive to these two kinds of drugs but not to others (i.e. puro-
mycin) (see Fig. 5, A–F) suggests that this phenotype caused by
Sho involves identical pathways/initial interacting partners to
the drug hypersensitivity induced by PrPCR (29, 46). This
contention is further supported by the fact that PrP-WT
coexpression non-variably eliminates these effects (29, 31,
51) (see Figs. 6 and 7) and by the increased initial Zeocin
uptake observed with both Sho (see Fig. 8) and PrPCR (29)
expression. This Sho-mediated hypersensitivity is especially
intriguing if one considers that no extended sequence simi-
larity exists between Shadoo and Doppel or between Shadoo
and PrPCR. In the latter, the only short segment that would
represent considerable sequence similarity between Sho and
PrP is deleted.
Furthermore, whereas PrPCR and Doppel are not
expressed physiologically in the CNS (16, 23), Shadoo is
expressed (17). Thus, our results support a view that this drug
hypersensitivity assay uncovers a pathwaywherein the function
of all three prion protein family members is preserved, suggest-
ing that this pathway may also be responsible for the mainte-
nance of a physiologically important process.
However, it is not clear whether the drug-sensitizing effects
of Sho expression in immortalized cells demonstrated here
operate in any of the prion-related pathological processes
found in vivo, such as TSEs or Alzheimer disease.
Relation to Other Toxic Phenotypes Associated with Mutant
or WT Prion Proteins—A handful of toxic phenotypes have
been described involving wild type and mutant prion proteins,
many of them being associated with the deletion of the hydro-
phobic domain or central region of PrP (7, 17, 20, 29, 31).One of
FIGURE 2. Analysis of the glycosylation, localization, and expression levels of prion proteins in SH/PrP-WT and SH/PrPCR cells. A, both PrP-WT and
PrPCR are present on the cell surface, and their expressions are coupledwith themarker EGFP. Shown are laser scanning confocalmicroscopy images. Nuclei
(blue) and PrPs (red) are stained by DAPI and SAF32 anti-PrP antibody, respectively. Scale bar, 40 m. B, both PrP-WT and PrPCR are complex-glycosylated.
Shown isWestern blotting analysis of extracts from various cells as indicated above the lanes, untreated () or treated () with PNGase F and visualized using
SAF32 anti-prion antibody. The higher mobility of PrPCR caused by the deletion of the central region (aa 105–125) is more apparent after a PNGase F
treatment. Endogenous PrP levels are below the detection limit.-Actin was used as loading control (bottom). C, both PrP-WT and PrPCR are attached to the
cell surface via aGPI anchor. Shown isWestern blotting analysis of extracts (cell lysate) and supernatantmedium (medium) fromvarious cells as indicated above
the lanes, untreated () or treated () with PI-PLC (top).-Actinwas used as loading control (bottom) in the case of cell lysates and todetect cell contamination
in supernatant medium samples (note that PrP coming from cell contamination remained below the detection limit in the case of PI-PLC-untreated samples).
A decrease in the PrP level is apparent in the lysates with a concurrent increase in the medium of PI-PLC-treated samples. B and C, numbers andmarks on the
left indicate the positions of the corresponding molecular size markers in kDa.
Drug Hypersensitivity Caused by the Shadoo Protein
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the most interesting questions is how these toxic phenotypes
seen in various systems relate to each other and to the neuro-
toxic effects seen in neurodegenerative diseases, such as TSE
and Alzheimer disease. Our results offer a way to distinguish
some of these pathways involved by the expression/coexpres-
sion of Sho.
Neurodegeneration in Mice Expressing Toxic Deletion
Mutant Forms of PrP—The strongest toxicity that appears
amongmice expressing the variousN-terminal deletionmutant
PrPs is associated with PrPCR, conferring a neonatal lethal
phenotype on a Prnp/ background characterized by sponta-
neous degeneration of CGNs as well as white matter pathology
in the brain and spinal cord (16).
Here, we found that Sho causes Zeocin/G418 hypersensi-
tivity in the absence of PrP-WT. If the same cellular path-
ways are used by PrPCR to cause both the Zeocin/G418
hypersensitivity in cell model systems and CGN degenera-
tion in mice, Sho-expressing Prnp-knock-out mice should
also show some overt phenotypes. This could be tested by
crossing Shadoo-overexpressing mice (52) with a Prnp-
knock-out background. It is worth noting that Prnp-null
mice that have endogenous Sho expression have no such
apparent phenotype (53); however, the endogenous expres-
sion levels of Sho are thought to be much lower than those of
PrP (see the AceViewWeb site), which might also contribute
to the absence of a clear phenotype.
Inward Cationic Currents Induced by PrPCR Expression—
Spontaneous ionic currents thatmay jeopardize the integrity of
the plasma membrane are detected with whole cell patch
clamping technique in a wide variety of cells of human, mouse,
and insect origin (HEK; N2a; CGN, neuronal stem cells, and
organotypic cerebellar slices from mice; Sf9 cells) that express
PrP bearing CR, Shmerling, or hydrophobic domain point
mutations associated with familial TSEs (30, 31). This pheno-
type is also rescued by the coexpression of PrP-WT. It would be
highly illuminating to learn whether Sho expression eliminates,
induces, or is indifferent to this effect (31).
Without such data available for Sho, it is hard to envisage the
possible molecular mechanism by which Sho exerts its sensiti-
zation effect observed here on SH-SY5Y and HEK293 cells. For
FIGURE 3. Coexpression of PrP-WT but not Sho diminishes PrPCR caused Zeocin hypersensitivity. A and B, PrPCR makes SH-SY5Y cells hyper-
sensitive to Zeocin. Shown are cytotoxicity assays, usingMTT reagent. A, representative experiment carried out at Zeocin concentrations between 0 and
100 g/ml on various cells, as indicated, for 48 h. Values are means S.D. (error bars) of replicas in the individual experiment. B, bars show the means
S.D. of cell viabilities measured at 6.25 g/ml Zeocin concentration in n  4 independent experiments. C and D, coexpression of PrP-WT but not Sho
diminishes PrPCR-caused Zeocin hypersensitivity. Shown is a cytotoxicity assay, using PrestoBlue reagent. C, representative experiment carried out at
Zeocin concentrations between 0 and 100 g/ml Zeocin on various cells as indicated for 48 h. Values are means  S.D. of replicas. D, bars show the
means S.D. of cell viabilities measured at 6.25 g/ml Zeocin concentration in n 3 independent experiments. A–D, 100% is the absorbance (A and B)
or fluorescence (C and D) value of untreated cells of each cell type. B and D, samples were compared with the leftmost values on each diagram (B,
SH-SY5Y; D, SH/CR); *, p  0.04; ***, p 	 0.001.
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FIGURE4.OverexpressedPrPCRandShohavenormal traffic and similar expression levels inSH-SY5Ycells.A, lentiviral transduction to express Shadoo
of PrPCR cells does not affect its proliferation adversely. Fluorescence of SH/CR, SH/CRSho, and SH/CRPrP cells was measured at every 24th h after
attachment for 8 days and inmultiplewells, using PrestoBlue reagent. A representative plot is shown. 100% is the fluorescence value at day 0 after attachment
for each type of cell. Values are means  S.D. of replicas in the individual experiment. B, both PrP-WT and PrPCR overexpressed in SH-SY5Y cells are
complex-glycosylated. PrPCR expression levels in SH/CR, SH/CRmCh, and SH/CRPrP cells are comparable. Shown is Western blotting analysis of
extracts from various cells as indicated above the lanes, untreated () or treated with PNGase F (). Left and right panels are from the same x-ray film,
corresponding to the left and right parts of the same membrane. C, Shadoo, overexpressed in SH/CRSho cells, is complex-glycosylated. Shown is Western
blotting analysis of extracts from SH/CRmCh and SH/CRSho cells, incubated with () or without () PNGase F or without incubation (0). After PNGase F
treatment, the C1 fragment (58) of Shadoo is more readily detectable. D, Shadoo protein is attached to the cell surface via a GPI anchor when expressed in
SH-SY5Y cells. Shown isWestern blotting analysis of cell lysates (Cl) and supernatantmedium (M) from SH/GFP (left) and SH/Sho (right) cells, incubatedwith ()
or without () PI-PLC. Endogenous Shadoo expression is below the detection limit. The amount of Shadoo decreases below the detection limit in the cell
samples of PI-PLC-treated cells (C versus C), whereas the amount of an intracellular protein, -actin, remains unchanged. Shadoo remains below the
detection limit in the medium samples. Left and right panels are from the same x-ray film, corresponding to the left and right parts of the same membrane. E,
positive control of PI-PLC treatment for D; PrP-WT is attached to the cell surface via a GPI anchor. Shown is Western blotting analysis of cell lysate (Cl) and
supernatant medium (M) from SH/PrP cells, untreated () or treated () with PI-PLC. A decrease in the PrP level is apparent in the lysates. Unlike Shadoo, PrP
can be detected in the medium after PI-PLC treatment. F, PrPCR expression level in SH/CRPrP is similar to PrP-WT and is lower than in SH/CRSho cells.
Comparison was carried out by Western blotting analysis of serial dilutions of extracts from SH/CRPrP (12, 6, and 3 g of total protein; left) and of extracts
from SH/CRSho (24, 12, 6, and 3g of total protein; right) treatedwith PNGase F. Left and right panels are from the same x-ray film, corresponding to the left
and right parts of the samemembrane.G, schematic design of rSho-PrP recombinant polypeptide. ThemSho(81–116) fragment is inserted intomPrP(23–231)
between the 93rd and 94th amino acids in order to produce a bacterially expressed polypeptide that contains epitopes for both Sho and PrP antibodies to
compare relative Shadoo and PrP protein levels. H, PrPCR and Shadoo expression levels of SH/CRSho cells are similar. Comparison was carried out by
Western blotting analysis of serial dilutions of extracts from SH/CRSho cells, treated with PNGase F, (24, 12, 6, or 3 g of total protein; left) and of rSho-PrP
recombinant polypeptide (200, 100, and 50 ng of purified recombinant protein; right). Left and right panels are from the same x-ray film, corresponding to the
left and right parts of the same membrane. B–F and H, *, a nonspecific band. Numbers and marks on the left indicate the positions of the corresponding
molecular size markers in kDa. As a loading control, -actin was used.
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PrPCR and related deletion mutants, the induction of inward
currents in cultured cells (30) and the possible pore formation
ability demonstrated on model membranes (54) point to one
possible mechanism of sensitization. In this respect, the N-ter-
minal region of PrP, especially the polybasic region 23–32,
proved to be essential (46). Sho resembling the N-terminal
domain of PrP also possesses a polybasic region, which pre-
cedes its hydrophobic domain. One could speculate that in a
similar manner to the N-terminal tail of PrP, Sho could also in
some circumstances exert sensitization through its basic region
that may or may not involve pore formation and increased
inward currents. The rescue effects of full-length PrP toward
sensitization by both PrPCR and Sho indicate that the rescue
processmay involve similarmolecularmechanisms. TheN-ter-
minal polybasic region of PrP proved to be critical for its neu-
roprotective effects as well, but a direct interaction of PrP with
the deletion mutant PrP32–134 in vivo did not take place in
the process (55). Using a yeast two-hybrid system, Jiayu et al.
(56) had shown that Sho can interact with the 108–126 region
of PrP, involving its aa 61–67 region, and Ciric et al. (57) dem-
onstrated that their interaction can interferewith the oligomer-
ization of PrP. One can also speculate that this binding,
although involving a different region of Sho, could silence
the sensitizing effects of the basic region of Sho while not
interfering with the N-terminal polybasic region of PrP,
hence resulting in a protective effect of PrP. However,
FIGURE 5. The overexpression of Shadoo, like PrPCR, sensitizes cells to Zeocin and G418. A–H, cytotoxicity assays, using PrestoBlue reagent. A and B,
SH-SY5Ycells expressingeither Shadoo (SH/Sho) or PrPCR (SH/CR) arehypersensitive toZeocin (48-h treatment).Of note, PrPCRexpression in SH/CRused
in this experimentwas lower than in the cells used for the experiments presentedonFig. 3 (data not shown).A, representative experiment carriedout at Zeocin
concentrations between 0 and 100 g/ml on various cells as indicated. B, bars show the means S.D. (error bars) of cell viabilities measured at 6.25 g/ml
Zeocin concentration in n 4 independent experiments. C and D, SH-SY5Y cells expressing either Shadoo (SH/Sho) or PrPCR (SH/CR) are hypersensitive to
G418 (48-h treatment). C, representative experiment carried out at G418 concentrations between 0 and 1000g/ml on various cells as indicated.D, bars show
themeans S.D. of cell viabilitiesmeasured at 250g/ml G418 concentration in n 3 independent experiments. E and F, neither SH/Sho nor SH/CR cells are
hypersensitive to puromycin (24-h treatment). E, representative experiment carried out at puromycin concentrations between 0 and 2g/ml on various cells
as indicated. F, bars show the means S.D. of cell viabilities measured at 1.6 g/ml puromycin concentration in n 6 independent experiments. G and H,
Shadoo induces G418 hypersensitivity in a dose-dependent manner (48-h treatment). G, representative experiment carried out at G418 concentrations
between0and1000g/mlon SH/Sho-low, SH/Sho-medium, and SH/Sho-high cells.H,bars show themeansS.D. of cell viabilitiesmeasuredat 250g/mlG418
concentration in n 3 independent experiments. a–h, 100% is the fluorescence value of untreated cells for each cell type. A, C, E, and G, values are means
S.D. of corresponding replicas within the experiment. B,D, F, andH, for testing significance, valueswere comparedwith the control (i.e. leftmost values on each
diagram) (SH/GFP (B and D) and SH-SY5Y (F and H)), and bars connected with brackets (H) were also compared using Tukey’s honest significant difference post
hoc test. *, p	 0.05; **, p	 0.01; ***, p	 0.001. I, relative Shadoo protein levels in SH/Sho cells. Shown isWestern blotting analysis of extracts from SH/Sho-low,
SH/Sho-medium, and SH/Sho-high as well as the parental SH/Sho and SH-SY5Y cells. *, a nonspecific band.Numbers andmarks on the left indicate the positions
of the corresponding molecular size markers in kDa. -Actin was used as a loading control.
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whether a direct binding of Sho and PrP takes place or not while
rescuing the sensitization effects of Sho in our system is not
known. The surprising and simultaneously intriguing findings
FIGURE 6. Coexpression of wild type PrP in SH/Sho cells eliminates
both Zeocin andG418 hypersensitivity caused by Shadoo expression.
A, SH/ShoGFP or SH/ShoPrP cells have slightly higher Shadoo expres-
sion than the parental SH/Sho cells. Shown is Western blotting analysis of
extracts from various cells as indicated above the lanes. Samples were
treated with PNGase F. B, PrP expression is detectable only in SH/ShoPrP
cells. Western blotting analysis of extracts from the same cells as in A.
Endogenous PrP is below the detection limit. A and B, *, a nonspecific
band. Numbers and marks on the left indicate the positions of the corre-
sponding molecular size markers in kDa. -Actin was used as a loading
control. C–F, cytotoxicity assays, using PrestoBlue reagent. C and D, coex-
pression of PrP but not EGFP diminishes Zeocin hypersensitivity caused by
Shadoo expression (48-h treatment). C, representative experiment carried
out at Zeocin concentrations between 0 and 100 g/ml on various cells as
indicated. D, bars show the means  S.D. (error bars) of cell viabilities
measured at 6.25 g/ml Zeocin concentration in n  4 independent
experiments. E and F, PrP coexpression diminishes G418 hypersensitivity
caused by Shadoo expression (48-h treatment). E, representative experi-
ment carried out at G418 concentrations between 0 and 1000 g/ml on
various cells, as indicated. F, bars show the means S.D. of cell viabilities
measured at 250 g/ml G418 concentration in n 3 independent exper-
iments. C–F, 100% is the fluorescence value of untreated controls of each
cell line. C and E, values are means S.D. of corresponding replicas within
the experiment. D and F, samples were compared with SH/Sho cells; *, p	
0.05; **, p 	 0.01; ***, p 	 0.001.
FIGURE 7.Shadooexpression causes Zeocin andG418hypersensitivity in
HEK293 cells that is eliminated by the coexpression of wild type PrP. A,
HEK/ShoGFP or HEK/ShoPrP cells have slightly higher Shadoo expression
than theparentalHEK/Sho cells. Shown isWesternblottinganalysis of extracts
from various cells as indicated above the lanes. *, a nonspecific band. B, PrP
expression is detectable only in HEK/ShoPrP cells. Shown is Western blot-
ting analysis of extracts from the same cells as in A after PNGase F treatment.
A and B, numbers and marks on the left indicate the positions of the corre-
sponding molecular size markers in kDa. -Actin was used as a loading con-
trol. C–F, cytotoxicity assays, using PrestoBlue reagent. C and D, Shadoo
expression causesZeocinhypersensitivity inHEK cells,which is diminishedby
the coexpression of PrP but not EGFP (48-h treatment). C, average of three
independent experiments carried out at Zeocin concentrations between 0
and 200g/ml on various cells as indicated.D, bars show themeans S.D. of
cell viabilities measured at 50g/ml Zeocin concentration in n 3 indepen-
dent experiments.Eand F, ShadooexpressioncausesG418hypersensitivity in
HEK cells that is diminished by the coexpression of PrP but not EGFP (48-h
treatment). E, average of three independent experiments carried out at G418
concentrations between 0 and 1000 g/ml on various cells as indicated. F,
bars show the means  S.D. (error bars) of cell viabilities measured at 250
g/ml G418 concentration in n 3 independent experiments. C–F, 100% is
the fluorescence value of untreated controls of each cell line. C and E, values
aremeans S.D. of three independent experiments.D and F, viabilities were
compared using a Tukey post hoc test after one-way analysis of variance;
asterisks above bars, difference when compared with HEK/Sho; brackets, sig-
nificant difference between compared cells; *, p	 0.05; ***, p	 0.001.
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presented here are remarkable for revealing a common cellular
pathway where the function of all three members of the prion
protein family seems to be preserved, suggesting that Sho might
help discern some of the mysterious facets of prion biology.
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